Literature DB >> 33350354

Usual opioid dosing does not adversely affect the course of healthcare-associated Clostridioides difficile infection.

Monica Chowdhry1, Douglas Haden2, Suzanne Kemper1, Kristen Helmick1, Muhammad Kawsara3, Ashley Huggett4, Andrea Stark1, Ahmad Khan1, Muhammad Shah5, Mustafa Bhaty6, Junaid Farooq1, Shailendra Singh1, Brittain McJunkin1.   

Abstract

Aim: We sought to determine if opioid exposure may have a detrimental effect on the course of Clostridioides difficile infection (CDI). Materials & methods: We compared opioid exposure in patients with well-defined severe CDI and non-severe CDI.
Results: Following exclusions, 403 records were reviewed. Of this group, 128/403 (31.7%) were determined to have severe CDI by strict criteria, and 275/403 (68.3%) were found to have non-severe CDI. Full multivariate regression and reduced model of potential predictors for severe CDI showed no association with opioids prescribed.
Conclusion: Opioid exposure (predominantly in modest range) does not appear to be a risk factor for severe healthcare-associated CDI.

Entities:  

Keywords:  Clostridium difficile infection; healthcare-associated infections; nosocomial infections; opioids; pain management; severe Clostridioides difficile infection

Mesh:

Substances:

Year:  2020        PMID: 33350354      PMCID: PMC8356678          DOI: 10.2217/pmt-2020-0066

Source DB:  PubMed          Journal:  Pain Manag        ISSN: 1758-1869


  22 in total

1.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

2.  Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.

Authors:  Abraham Goorhuis; Dennis Bakker; Jeroen Corver; Sylvia B Debast; Celine Harmanus; Daan W Notermans; Aldert A Bergwerff; Frido W Dekker; Ed J Kuijper
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

Review 3.  Gut Homeostasis, Microbial Dysbiosis, and Opioids.

Authors:  Fuyuan Wang; Sabita Roy
Journal:  Toxicol Pathol       Date:  2016-11-28       Impact factor: 1.902

Review 4.  Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection.

Authors:  Charlesnika T Evans; Nasia Safdar
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

5.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

6.  The Social and Functional Implications of High- Versus Low-Dose Opioids on Chronic Non-Cancer Pain.

Authors:  Yohei Denawa; Will Kurtz; Till Conermann
Journal:  Pain Physician       Date:  2019-07       Impact factor: 4.965

7.  Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein.

Authors:  Christian Hardt; Thomas Berns; Wolfgang Treder; Franz-Ludwig Dumoulin
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

8.  Clinical factors associated with development of severe-complicated Clostridium difficile infection.

Authors:  Raina Shivashankar; Sahil Khanna; Patricia P Kammer; W Scott Harmsen; Alan R Zinsmeister; Larry M Baddour; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-20       Impact factor: 11.382

9.  Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation.

Authors:  S Banerjee; G Sindberg; F Wang; J Meng; U Sharma; L Zhang; P Dauer; C Chen; J Dalluge; T Johnson; S Roy
Journal:  Mucosal Immunol       Date:  2016-02-24       Impact factor: 7.313

Review 10.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.

Authors:  Deborah Dowell; Tamara M Haegerich; Roger Chou
Journal:  JAMA       Date:  2016-04-19       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.